SciVision Biotech Inc. announced that Flexotron Forte(1%), hyaluronic acid developed and produced by the company, has passed and obtained the medical device license (P3H 2022/17365). This product contains hyaluronic acid, which can increase joint lubrication and reduce joint friction. For the majority of patients with degenerative knee arthritis, it can inhibit the degeneration of cartilage, promote its metabolism, relieve pain and discomfort, improve daily activities and increase range of activities of joints.

Russia has a population of 147 million, of which about 13% have osteoarthritis. The company has obtained the Russian national medical device license, which can increase the sales performance in the Russian market and contribute to the company's revenue.